KalVista Pharmaceuticals, Inc. (KALV)
NASDAQ: KALV · Real-Time Price · USD
20.29
+0.70 (3.57%)
At close: Apr 14, 2026, 4:00 PM EDT
20.61
+0.32 (1.55%)
After-hours: Apr 14, 2026, 6:50 PM EDT
KalVista Pharmaceuticals Employees
KalVista Pharmaceuticals had 275 employees as of December 31, 2025. The number of employees increased by 5 or 1.85% since the number was reported on April 30, 2025.
Employees
275
Change
5
Growth
1.85%
Revenue / Employee
$267,698
Profits / Employee
-$597,404
Market Cap
1.04B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 275 | 5 | 1.85% |
| Apr 30, 2025 | 270 | 120 | 80.00% |
| Apr 30, 2024 | 150 | 32 | 27.12% |
| Apr 30, 2023 | 118 | 13 | 12.38% |
| Apr 30, 2022 | 105 | 35 | 50.00% |
| Apr 30, 2021 | 70 | 14 | 25.00% |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jul 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Xeris Biopharma Holdings | 435 |
| Phathom Pharmaceuticals | 371 |
| UroGen Pharma | 291 |
| Septerna | 130 |
| ORIC Pharmaceuticals | 104 |
| Annexon | 96 |
| Inventiva | 84 |
| GH Research | 73 |
KALV News
- 6 days ago - KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference - Business Wire
- 12 days ago - KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 15 days ago - KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference - Business Wire
- 20 days ago - KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update - Business Wire
- 25 days ago - KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference - Business Wire
- 27 days ago - KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026 - Business Wire
- 6 weeks ago - KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat) - Business Wire
- 6 weeks ago - KalVista Pharmaceuticals to Present at Upcoming Investor Conferences - Business Wire